Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1750-1326
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome ; volume:12 ; number:1 ; day:4 ; month:9 ; year:2017 ; pages:1-11 ; date:12.2017
Molecular neurodegeneration ; 12, Heft 1 (4.9.2017), 1-11, 12.2017
- Schlagwort
-
Hirnkrankheit
Neuropsychiatrie
Nervenkrankheit
- Urheber
-
Tatebe, Harutsugu
- Beteiligte Personen und Organisationen
-
Kasai, Takashi
Ohmichi, Takuma
Kishi, Yusuke
Kakeya, Tomoshi
Waragai, Masaaki
Kondō, Masaki
Allsop, David
Tokuda, Takahiko
SpringerLink (Online service)
- DOI
-
10.1186/s13024-017-0206-8
- URN
-
urn:nbn:de:1111-2017110414788
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:35 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tatebe, Harutsugu
- Kasai, Takashi
- Ohmichi, Takuma
- Kishi, Yusuke
- Kakeya, Tomoshi
- Waragai, Masaaki
- Kondō, Masaki
- Allsop, David
- Tokuda, Takahiko
- SpringerLink (Online service)
Ähnliche Objekte (12)
Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas
Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progression
Scientific commentary on: “Phosphorylated tau in the retina correlates with tau pathology in the brain in Alzheimer’s disease and primary tauopathies”
Propagation of Tau pathology in Alzheimer disease
Biological mechanisms of resilience to tau pathology in Alzheimer’s disease
Association between polygenic risk score of Alzheimer’s disease and plasma phosphorylated tau in individuals from the Alzheimer’s Disease Neuroimaging Initiative
Phosphorylated tau in cerebrospinal fluid-derived extracellular vesicles in Alzheimer’s disease: a pilot study
CSF p-tau205: a biomarker of tau pathology in Alzheimer’s disease
Global neuropathologic severity of Alzheimer’s disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels
Inhibition of CK2 mitigates Alzheimer’s tau pathology by preventing NR2B synaptic mislocalization
Molecular mechanisms of Tau and TDP-43 co-pathology in Alzheimer´s disease
Brain vasculature accumulates tau and is spatially related to tau tangle pathology in Alzheimer’s disease
Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas
Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progression
Scientific commentary on: “Phosphorylated tau in the retina correlates with tau pathology in the brain in Alzheimer’s disease and primary tauopathies”
Propagation of Tau pathology in Alzheimer disease
Biological mechanisms of resilience to tau pathology in Alzheimer’s disease
Association between polygenic risk score of Alzheimer’s disease and plasma phosphorylated tau in individuals from the Alzheimer’s Disease Neuroimaging Initiative
Phosphorylated tau in cerebrospinal fluid-derived extracellular vesicles in Alzheimer’s disease: a pilot study
CSF p-tau205: a biomarker of tau pathology in Alzheimer’s disease
Global neuropathologic severity of Alzheimer’s disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels
Inhibition of CK2 mitigates Alzheimer’s tau pathology by preventing NR2B synaptic mislocalization
Molecular mechanisms of Tau and TDP-43 co-pathology in Alzheimer´s disease
Brain vasculature accumulates tau and is spatially related to tau tangle pathology in Alzheimer’s disease
Amyloid-beta and phosphorylated tau in post-mortem Alzheimer’s disease retinas
Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progression
Scientific commentary on: “Phosphorylated tau in the retina correlates with tau pathology in the brain in Alzheimer’s disease and primary tauopathies”
Propagation of Tau pathology in Alzheimer disease
Biological mechanisms of resilience to tau pathology in Alzheimer’s disease
Association between polygenic risk score of Alzheimer’s disease and plasma phosphorylated tau in individuals from the Alzheimer’s Disease Neuroimaging Initiative
Phosphorylated tau in cerebrospinal fluid-derived extracellular vesicles in Alzheimer’s disease: a pilot study
CSF p-tau205: a biomarker of tau pathology in Alzheimer’s disease
Global neuropathologic severity of Alzheimer’s disease and locus coeruleus vulnerability influences plasma phosphorylated tau levels
Inhibition of CK2 mitigates Alzheimer’s tau pathology by preventing NR2B synaptic mislocalization
Molecular mechanisms of Tau and TDP-43 co-pathology in Alzheimer´s disease